Harel Insurance Investments & Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-802	Closed	-$50K	–	518
2019 Q3	$50K	Hold	802	–	–	﹤0.01%	307
2019 Q2	$57K	Hold	802	–	–	﹤0.01%	289
2019 Q1	$63K	Hold	802	–	–	﹤0.01%	253
2018 Q4	$68K	Buy	+802	New	+$85.5K	﹤0.01%	270

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Harel Insurance Investments & Financial Services's LGND Position: Q4 2019 in Review

Harel Insurance Investments & Financial Services sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 802 shares — an estimated $50K sold.

Harel Insurance Investments & Financial Services first reported a position in LGND in Q4 2018 and held it in 4 quarters. The position peaked at $68K in Q4 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

Harel Insurance Investments & Financial Services reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 802 Ligand Pharmaceuticals shares in Q4 2019, an estimated $50K.
Harel Insurance Investments & Financial Services first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Harel Insurance Investments & Financial Services's Ligand Pharmaceuticals position peaked at $68K in Q4 2018.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2019, filed 23 Jan 2020.